Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02307630 · ClinicalTrials.gov registry record · NA
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
A NA study of Melanoma and Sarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT02307630: Active NA study of Melanoma and Sarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02307630 is a NA study of Melanoma and Sarcoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 7 participants, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02307630, a NA study of Melanoma and Sarcoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out how an antibody called Hu3F8 travels through the body and to tumors. Antibodies, like Hu3F8, are proteins that help attack tumors or fight infections. Antibodies can be made by your own body or in a laboratory. The target of an antibody is called an antigen; antibodies fit their antigen like a lock fits a key.
Primary Outcome
Following 124I-hu3F8 administration, upon completion of normal saline flush, blood will be drawn for pharmacokinetic studies at the following time points: 0h, 0.5h, 1h, 2h, 4-8h, 24h, 48h, 96h and 120-144 h.after injection of 124I-hu3F8 and radioactivity measured to determine pharmacokinetics of 124I-hu3F8.
Conditions Studied
Interventions
- BIOLOGICAL 124I-Humanized 3F8
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-11 |
| Est. Completion | 2026-11 |
| Phase | NA |
What the registry record for NCT02307630 still lists
NCT02307630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which 124I-Humanized 3F8 is the first listed.
NCT02307630 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02307630 about?
NCT02307630 is a clinical study titled "PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study". The purpose of this study is to find out how an antibody called Hu3F8 travels through the body and to tumors. Antibodies, like Hu3F8, are proteins that help attack tumors or fight infections. Antibodies can be made by your own body or in a laboratory. The target of an antibody is called an antigen; ...
What is the current status of trial NCT02307630?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 7 participants. The study started on 2014-11. Estimated completion is 2026-11.
What conditions does trial NCT02307630 study?
This clinical trial studies the following conditions: Melanoma, Sarcoma, Neuroblastoma.
What interventions are being tested in trial NCT02307630?
The interventions under investigation include: 124I-Humanized 3F8 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02307630?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02307630 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02307630's enrollment target sits among peer trials
7 258th of 266 higher than 7 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
RECRUITING · NA
-
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
RECRUITING · NA
-
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia